α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia

Journal of Urology

Volumn 161, Issue 6, 1999, Pages 2002-2008

  Chon, Joanna K ^b   Borkowski, Andrew ^b   Partin, Alan W ^b   Isaacs, John T ^b   Jacobs, Stephen C ^b   Kyprianou, Natasha ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Apoptosis; Cell proliferation; Doxazosin; Prostate; Terazosin; adrenoceptor antagonists

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TERAZOSIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; STROMA;

EID: 0032861498     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68873-8     Document Type: Article

References (36)

1. Kyprianou, N., Litvak, J. P., Borkowski, A., Alexander R. and Jacobs, S. C.: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia, J. Urol., 159: 1810, 1998.
2. Lepor, H.: The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol., 81: 29, 1998.
3. Oesterling, J. E.: Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate (Suppl.), 6: 67, 1996.
4. McNeal, J. E.: Origin and evolution of benign prostatic enlargement. Invest. Urol., 15: 340, 1978.
5. Caine, M.: Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology, 32: 16, 1988.
6. McConnell, J. D.: Medical management of benign prostatic hyperplasia with androgen suppression, Prostate (Suppl.), 3: 49, 1990.
7. Isaacs, J. T. and Coffey, D. S.: Etiology and disease process of benign prostatic hyperplasia. Prostate (Suppl.), 2: 33, 1989.
8. Peters, C. A. and Walsh, P. C.: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia [published erratum appears in N. Engl. J. Med. 3, 318: 580], N. Engl. J. Med., 317: 599, 1987.
9. Lepor, H., Tang, R. and Shapiro, E.: The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate, 22: 301, 1993.
10. Caine, M., Pfau, A. and Perlberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol., 48: 255, 1976, 1976.
11. Andersson, K-E., Lepor, H. and Wyllie, M. G.: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate, 30: 202, 1997.
12. Chapple, C. R., Burt, R. P., Andersson, P. O., Greengrass, P., Wyllie, M. and Marshall, I. Alpha 1-adrenoceptor subtypes in the human prostate. Br. J. Urol., 74: 585, 1994.
13. Lepor, H., Tang, R., Meretyk, S. and Shapiro, E.: Alpha 1 adrenoceptor subtypes in the human prostate, J. Urol., 149: 640, 1993.
14. Lepor, H. and Shapiro, E.: Prostatic alpha adrenoceptors, Prog. Clin. Biol. Res., 386: 271,1994.
15. 1-antagonists, Br. J. Urol., 81: 48, 1998.
16. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study [see comments]. J. Urol., 154: 105, 1995.
17. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K. and Dias, N.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study [see comments]. J. Urol., 154: 110, 1995.
18. Lepor, H., Kaplan, S. A., Klimberg, I., Mobley, D. F., Fawzy, A., Gaffney, M., Ice, K. and Dias, N.: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J. Urol., 157: 525, 1997.
19. Berges, R. R., Vucanovic, J., Epstein, J. I., Walsh, P. C. and Isaacs, J. T.: Implication of cell cycle kinetic changes during the progresssion of human prostate cancer., Clin. Cancer Res., 1: 473, 1995.
20. Kyprianou, N., Tu, H. and Jacobs, S. C.: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Pathol., 27: 668,1996.
21. Arends, M. J. and Wyllie, A. H.: Apoptosis: mechanisms and roles in pathology. International Rev. Exp. Pathol., 32: 223, 1991.
22. Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M. and Korsmeyer, S. J.: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Nat. Acad. Sci. USA, 88: 6961, 1992.
23. McConnell, J. D., Barry, M. J. and Bruskewitz, R. C.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994.
24. Barry, M. J., Fowler, F. J., Jr., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K. and Cockett, A. T.: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol., 148: 1549, 1992.
25. Lepor, H., Nieder, A., Feser, J. and Dixon, C.: Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology, 49: 476, 1997.
26. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P. and Padley, R. J.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments]. N. Engl. J. Med., 335: 533, 1996.
27. Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Lloyd, L. K., Milam, D. E. and Padley, R. J.: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology, 47: 159, 1996.
28. Janknegt, R. A. and Chapple, C. R.: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur. Urol., 24: 319, 1993.
29. Yang, G., Timme, T. L., Park, S. H., Wu, X., Wyllie, M. G. and Thompson, T. C.: Transforming growth factor betal transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin [see comments]. Prostate, 33: 157, 1997.
30. Shapiro, E., Hartanto, V. and Lepor, H.: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J. Urol., 147: 1167, 1992.
31. Timme, T. L., Truong, L. D., Merz, V. W., Krebs, T., Kadmon, D., Flanders, K. C., Park, S. H. and Thompson, T. C.: Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinol., 134: 1039, 1994.
32. Yang, G., Timme, T. L., Park, S. H. and Thompson, T. C.: Transforming growth factor beta 1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes [see comments]. Prostate, 33: 151, 1997.
33. Flanders, K. C., Ludecke, G., Engels, S., Cissel, D. S., Roberts, A. B., Kondaiah, P., Lafyatis, R., Sporn, M. B. and Unsicker, K.: Localization and actions of transforming growth factor-beta in the embryonic nervous system. Development, 113: 183, 1991.
34. Chalazonitis, A., Kalberg, J., Twardzik, D. R., Morrison, R. S. and Kessler, J. A.: Transforming growth factor beta has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor. Dev. Biol., 152: 121, 1992.
35. Price, H., McNeal, J. E. and Stamey, T. A.: Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Pathol., 21: 578, 1990.
36. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M. and Waldstreicher, J.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group [see comments]. N. Engl. J. Med., 338: 557, 1998.